drugset / Trial / NCT00061425
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
Timeline
- Start
- 2000-08
- Primary completion
- 2007-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epratuzumab | Monoclonal antibody | — | — |